Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification to the U.S. Securities and Exchange Commission regarding the submission of its Annual Report on Form 20-F. The filing, dated March 20, 2017, covers the period ending March 20, 2017, and references the company's audited financial statements for the fiscal year ended December 31, 2016.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It solely announces the availability of the 2016 Annual Report containing these audited figures.
Material Changes
No material changes in financial performance or operations are detailed in this specific document. The filing acts as a procedural notice rather than a financial performance report.
Guidance, Outlook, and Risks
GSK includes a cautionary statement regarding forward-looking statements, noting that projections are subject to risks and uncertainties that may cause actual results to differ materially. The filing directs investors to Item 3.D "Risk factors" in the 2016 Annual Report on Form 20-F for a detailed description of these risks. No specific guidance or management commentary on future outlook is provided in this text.
Investor Verification Checklist
- Verify the availability of the full 2016 Annual Report on Form 20-F on GSK's website (www.gsk.com/corporatereporting) or the SEC website (www.sec.gov).
- Review Item 3.D "Risk factors" within the Form 20-F for detailed risk disclosures.
- Confirm the date of the Annual General Meeting and the availability of hard copies of the Annual Summary via the registrars (Equiniti Limited) or ADR depositary (BNY Mellon).
- Check for any subsequent updates to the audited financial statements for the year ended December 31, 2016.